INNOPHARMAX INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 17.4 TWD | -1.97% |
|
+3.88% | 0.00% |
| 04-19 | InnoPharmax Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| 2023 | InnoPharmax Inc. Reports Earnings Results for the Half Year Ended June 30, 2023 | CI |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 517.8 | 860.7 | 1,309 | 1,509 | 1,016 | 1,653 |
| Enterprise Value (EV) 1 | 418.3 | 726 | 1,097 | 1,327 | 949 | 1,535 |
| P/E ratio | -5.97 x | -9.84 x | -29.8 x | -16.1 x | -9.83 x | -22.6 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 9.17 x | 10.1 x | 9.56 x | 31.4 x | 34.9 x | 35.9 x |
| EV / Revenue | 7.4 x | 8.55 x | 8.01 x | 27.6 x | 32.6 x | 33.3 x |
| EV / EBITDA | -5.92 x | -10.9 x | -53.5 x | -19.1 x | -10.6 x | -24.7 x |
| EV / FCF | -9.7 x | -69.3 x | 11.9 x | -8.34 x | -16.9 x | -44.4 x |
| FCF Yield | -10.3% | -1.44% | 8.38% | -12% | -5.93% | -2.25% |
| Price to Book | 0.95 x | 1.81 x | 2.78 x | 2.84 x | 2.36 x | 3.48 x |
| Nbr of stocks (in thousands) | 70,546 | 70,546 | 76,546 | 86,719 | 86,836 | 94,999 |
| Reference price 2 | 7.340 | 12.20 | 17.10 | 17.40 | 11.70 | 17.40 |
| Announcement Date | 4/22/19 | 4/30/20 | 4/13/21 | 4/13/22 | 3/6/23 | 4/19/24 |
1TWD in Million2TWD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 56.49 | 84.89 | 136.9 | 48.06 | 29.13 | 46.07 |
| EBITDA 1 | -70.64 | -66.37 | -20.52 | -69.32 | -89.41 | -62.12 |
| EBIT 1 | -80.25 | -74.95 | -30.32 | -74.37 | -93.33 | -64.84 |
| Operating Margin | -142.06% | -88.29% | -22.15% | -154.76% | -320.35% | -140.73% |
| Earnings before Tax (EBT) 1 | -86.35 | -87.89 | -43.9 | -92.96 | -103.2 | -70.83 |
| Net income 1 | -86.35 | -87.89 | -43.9 | -92.96 | -103.2 | -70.83 |
| Net margin | -152.86% | -103.54% | -32.07% | -193.44% | -354.17% | -153.74% |
| EPS 2 | -1.230 | -1.240 | -0.5735 | -1.080 | -1.190 | -0.7700 |
| Free Cash Flow 1 | -43.13 | -10.47 | 91.88 | -159.1 | -56.27 | -34.59 |
| FCF margin | -76.35% | -12.33% | 67.13% | -331.08% | -193.15% | -75.07% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 4/22/19 | 4/30/20 | 4/13/21 | 4/13/22 | 3/6/23 | 4/19/24 |
1TWD in Million2TWD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - |
| Net Cash position 1 | 99.5 | 135 | 212 | 182 | 67 | 118 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | -43.1 | -10.5 | 91.9 | -159 | -56.3 | -34.6 |
| ROE (net income / shareholders' equity) | -14.7% | -16.6% | -8.9% | -18.5% | -21.4% | -15.6% |
| ROA (Net income/ Total Assets) | -8.13% | -7.93% | -2.97% | -7.52% | -11.2% | -8% |
| Assets 1 | 1,062 | 1,108 | 1,479 | 1,236 | 924.7 | 885.7 |
| Book Value Per Share 2 | 7.700 | 6.730 | 6.160 | 6.130 | 4.960 | 5.010 |
| Cash Flow per Share 2 | 0.9800 | 1.650 | 2.370 | 1.040 | 0.4700 | 0.4100 |
| Capex 1 | 0.3 | - | - | 1.45 | - | 0.4 |
| Capex / Sales | 0.54% | - | - | 3.02% | - | 0.86% |
| Announcement Date | 4/22/19 | 4/30/20 | 4/13/21 | 4/13/22 | 3/6/23 | 4/19/24 |
1TWD in Million2TWD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| 0.00% | 50.81M | |
| +20.78% | 43.29B | |
| +27.64% | 22.38B | |
| +19.03% | 15.51B | |
| +18.68% | 14.52B | |
| +54.64% | 12.93B | |
| -0.05% | 6.79B | |
| -11.39% | 6.56B | |
| +17.73% | 5.87B | |
| -8.87% | 5.73B |
- Stock Market
- Equities
- 4172 Stock
- Financials InnoPharmax Inc.
